Hormonal
Activation of the alternative bile acid synthetic pathway, specifically via increased CYP7B1 expression and non-12α-hydroxylated bile acids (e.g., CDCA, TUDCA), improves glucose and lipid metabolism by reducing lipid absorption and enhancing energy expenditure.
Focus on dietary patterns or interventions that support the alternative bile acid pathway, such as consuming polyphenol-rich foods like Pu-erh tea (theabrownin) or fermented foods that may influence gut microbiota bile salt hydrolase activity. This shift favors non-12α-hydroxylated bile acids, which are associated with improved glucose tolerance and reduced lipid absorption in metabolic disease contexts.
activation of the BA alternative pathway had beneficial effects on glucose and lipid metabolism... increased BA synthesis decreased cholesterol levels and also increased the excretion of fecal BAs
Why this rating
The paper is a review summarizing multiple studies, including mouse models and some human observational data, but lacks large-scale randomized controlled trials for most interventions.
Source
Targeting the alternative bile acid synthetic pathway for metabolic diseases
Wei Jia et al. · Protein & Cell · 2020
DOI 10.1007/s13238-020-00804-9
More from this paper
- Inhibition of intestinal bile salt hydrolase (BSH) activity by compounds like theabrownin or riboflavin increases conjugated bile acids in the distal ileum, which inhibits intestinal FXR signaling and upregulates hepatic CYP7B1, thereby promoting the alternative bile acid pathway.Moderate
- High levels of 12α-hydroxylated bile acids (derived from the classical pathway) are associated with metabolic disorders like insulin resistance and type 2 diabetes, whereas a higher ratio of non-12α-hydroxylated bile acids is beneficial.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →